Evogene LTD. (EVGN) — SEC Filings

Overview

Evogene LTD. (EVGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 16, 2026: Evogene Ltd. filed an EFFECT form on April 16, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-001196, relates to Act 33 and File No. 333-294650. The company's business address is 13 Gad Feinstein Street Park, Rehovot, Israel.

Sentiment Summary

Across 46 filings, the sentiment breakdown is: 3 bullish, 43 neutral. The dominant filing sentiment for Evogene LTD. is neutral.

Filing Type Overview

Evogene LTD. (EVGN) has filed 2 EFFECT, 40 6-K, 2 20-F, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (46)

• Evogene Ltd. Filing Effectiveness Notice — EFFECT · Apr 16, 2026 Risk: low
  Evogene Ltd. filed an EFFECT form on April 16, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-0
• Evogene Ltd. Filing Becomes Effective — EFFECT · Apr 6, 2026 Risk: low
  Evogene Ltd. filed an EFFECT form on April 6, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-00
• 6-K Filing — 6-K · Dec 30, 2025
• Evogene Ltd. Reports Q3 2025 Financial Results — 6-K · Nov 20, 2025 Risk: low
  Evogene Ltd. announced its financial results for the third quarter ended September 30, 2025, on November 20, 2025. The company filed a Form 6-K report with the
• Evogene Ltd. Files 6-K for H1 2025 Results — 6-K · Sep 30, 2025 Risk: low
  Evogene Ltd. filed a Form 6-K on September 30, 2025, reporting its results of operations for the six months ended June 30, 2025. The filing is for a foreign pri
• Evogene Ltd. Files September 2025 6-K Report — 6-K · Sep 10, 2025 Risk: low
  Evogene Ltd. filed a Form 6-K on September 10, 2025, reporting for the month of September 2025. The filing is a report of a foreign private issuer and includes
• Evogene Ltd. Reports Q2 2025 Financial Results — 6-K · Aug 19, 2025 Risk: low
  Evogene Ltd. announced its financial results for the second quarter ended June 30, 2025, on August 19, 2025. The company filed a Form 6-K report with the SEC to
• Evogene Shareholders Approve All Proposals at Annual Meeting — 6-K · Aug 18, 2025 Risk: low
  Evogene Ltd. announced on August 18, 2025, that its shareholders approved all proposals at the annual general meeting. This meeting, which was adjourned for one
• Evogene Annual Meeting Adjourned Due to Lack of Quorum — 6-K · Aug 11, 2025 Risk: low
  Evogene Ltd. held its Annual General Meeting of Shareholders on August 11, 2025, but it was adjourned for one week due to a lack of quorum. The meeting will now
• Evogene Ltd. Files Proxy Card for August 11 AGM — 6-K · Jul 17, 2025 Risk: low
  Evogene Ltd. filed a supplemental submission of a proxy card for its Annual General Meeting of Shareholders, scheduled for August 11, 2025. This filing follows
• Evogene's Lavie Bio Sells Most Operations to ICL — 6-K · Jul 8, 2025 Risk: medium
  On July 8, 2025, Evogene Ltd. announced that its subsidiary, Lavie Bio Ltd., completed a transaction with Dead Sea Works Ltd., an affiliate of ICL Group Ltd. (I
• Evogene Ltd. Announces Annual Shareholder Meeting Date — 6-K · Jun 17, 2025 Risk: low
  Evogene Ltd. has filed a Form 6-K on June 17, 2025, to announce its Annual General Meeting of Shareholders. The meeting is scheduled for August 11, 2025, at 3:0
• Evogene Subsidiary Biomica CEO Steps Down Due to Medical Reasons — 6-K · Jun 5, 2025 Risk: medium
  Evogene Ltd. announced changes in its subsidiary Biomica Ltd.'s management on June 5, 2025. Dr. Elran Haber is stepping down as CEO of Biomica due to an unexpec
• Evogene Ltd. Reports Q1 2025 Financial Results — 6-K · May 21, 2025 Risk: low
  Evogene Ltd. announced its financial results for the first quarter ended March 31, 2025, on May 21, 2025. The company, headquartered in Rehovot, Israel, is a fo
• Evogene Sells Lavie Bio Assets to ICL for $15.25M — 6-K · Apr 21, 2025 Risk: medium
  On April 21, 2025, Evogene Ltd. announced the sale of most of its subsidiary Lavie Bio Ltd.'s activities to Dead Sea Works Ltd., an affiliate of ICL Group Ltd.,
• Evogene Ltd. Files 20-F, Details 2024 Financials & Stock Split — 20-F · Mar 27, 2025 Risk: medium
  Evogene Ltd. filed its 20-F annual report for the fiscal year ending December 31, 2024. The company, incorporated in L3 and headquartered in Rehovot, Israel, op
• Evogene Ltd. Board Chair Steps Down — 6-K · Mar 6, 2025 Risk: low
  Evogene Ltd. announced on March 6, 2025, that Sarit Firon has stepped down as Chairperson of the Board. The company filed a Form 6-K to report this change in it
• Evogene Ltd. Shareholders Approve Key Proposal — 6-K · Feb 12, 2025 Risk: low
  Evogene Ltd. announced on February 12, 2025, that its shareholders approved a proposal at a special general meeting. This meeting was originally scheduled for a
• Evogene Ltd. Meeting Adjourned Due to Lack of Quorum — 6-K · Feb 5, 2025 Risk: low
  Evogene Ltd. held a Special General Meeting of Shareholders on February 5, 2025, which was adjourned for one week due to a lack of quorum. The meeting will now
• Evogene Ltd. Announces Executive Departure Amid Restructuring — 6-K · Jan 15, 2025 Risk: low
  Evogene Ltd. announced that Eyal Ronen, Executive Vice President of Business Development, will be leaving the company effective March 4, 2025, as part of an org
• Evogene Ltd. Schedules Special Shareholder Meeting for Feb 5, 2025 — 6-K · Dec 30, 2024 Risk: low
  Evogene Ltd. has announced a special general meeting of shareholders scheduled for February 5, 2025, at 3:00 p.m. Israel time. The meeting will be held at Evoge
• Evogene Subsidiary Lavie Bio's Licensing Deal Terminated by Corteva — 6-K · Nov 27, 2024 Risk: medium
  On November 27, 2024, Evogene Ltd. announced that its subsidiary, Lavie Bio Ltd., received a notice of termination from Corteva Agriscience LLC regarding a lice
• Evogene Ltd. Reports Q3 2024 Financial Results — 6-K · Nov 21, 2024 Risk: low
  Evogene Ltd. announced its financial results for the third quarter ended September 30, 2024, on November 21, 2024. The company, which operates in the agricultur
• SC 13G/A Filing — SC 13G/A · Oct 15, 2024
• Evogene Ltd. CTO Mark Kapel to Depart — 6-K · Sep 17, 2024 Risk: low
  Evogene Ltd. announced on September 17, 2024, that Chief Technology Officer Mark Kapel will leave the company effective October 31, 2024, as part of an organiza
• Evogene Ltd. Files 6-K with Q2 Financials — 6-K · Sep 16, 2024 Risk: low
  Evogene Ltd. filed a Form 6-K on September 16, 2024, to furnish unaudited condensed consolidated financial statements for the period ending June 30, 2024. The f
• Evogene Ltd. Raises Capital Through Share Offering — 6-K · Aug 23, 2024 Risk: medium
  On August 23, 2024, Evogene Ltd. entered into a securities purchase agreement to issue and sell 265,000 ordinary shares to an institutional investor in a regist
• Evogene Ltd. Reports Q2 2024 Financial Results — 6-K · Aug 22, 2024 Risk: low
  Evogene Ltd. announced its financial results for the second quarter ended June 30, 2024, on August 22, 2024. The company is a foreign private issuer filing a Fo
• Evogene Regains Nasdaq Minimum Bid Price Compliance — 6-K · Aug 12, 2024 Risk: low
  Evogene Ltd. announced on August 8, 2024, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per s
• Evogene Ltd. Announces 1-for-10 Reverse Share Split — 6-K · Jul 23, 2024 Risk: medium
  Evogene Ltd. announced on July 23, 2024, that it will implement a 1-for-10 reverse share split. This action will consolidate every ten ordinary shares into one,
• Evogene Subsidiary Casterra Secures $440K Order — 6-K · Jun 25, 2024 Risk: low
  Evogene Ltd. announced on June 25, 2024, that its subsidiary, Casterra AG Ltd., received an additional purchase order worth approximately $440,000 from an exist
• Evogene Ltd. CPO Nir Arbel to Step Down — 6-K · Jun 20, 2024 Risk: low
  Evogene Ltd. announced that Nir Arbel, the Chief Product Officer, will step down from his position on August 15, 2024, due to relocation. The company is current
• Evogene Shareholders Approve Proposals, Reject CEO Stock Options — 6-K · Jun 17, 2024 Risk: low
  Evogene Ltd. held its annual general meeting of shareholders on June 13, 2024, where all proposals were approved, except for the resolution regarding the grant
• Evogene Annual Meeting Adjourned Due to Lack of Quorum — 6-K · Jun 6, 2024 Risk: low
  Evogene Ltd. held its Annual General Meeting of Shareholders on June 6, 2024, but it was adjourned for one week due to a lack of quorum. The meeting will now re
• Evogene Ltd. Files May 2024 6-K Report — 6-K · May 29, 2024 Risk: low
  Evogene Ltd. filed a Form 6-K on May 29, 2024, for the month of May 2024. The filing is a report of a foreign private issuer and includes Exhibit 99.1. Evogene
• Evogene Ltd. Reports Q1 2024 Financial Results — 6-K · May 23, 2024 Risk: low
  Evogene Ltd. announced its financial results for the first quarter ended March 31, 2024, on May 23, 2024. The company filed a Form 6-K report with the SEC to fu
• Evogene Ltd. Schedules 2024 Annual Shareholder Meeting — 6-K · Apr 30, 2024 Risk: low
  Evogene Ltd. announced its 2024 annual general meeting of shareholders will be held on Thursday, June 6, 2024, at 3:00 p.m. Israel time at its offices. The comp
• Evogene Launches Finally Foods for Plant-Based Protein — 6-K · Apr 2, 2024 Risk: medium
  Evogene Ltd. announced on April 2, 2024, the establishment of Finally Foods Ltd., a new company specializing in plant-based protein production for the food indu
• Evogene Ltd. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 28, 2024 Risk: low
  Evogene Ltd. (EVGN) filed a Foreign Annual Report (20-F) with the SEC on March 28, 2024. Evogene Ltd. filed its 20-F annual report for the fiscal year ending De
• Evogene Ltd. Receives Nasdaq Letter — 6-K · Mar 20, 2024 Risk: medium
  On March 20, 2024, Evogene Ltd. announced it received a letter from the Nasdaq Stock Market LLC. The filing does not specify the content or implications of this
• Evogene Ltd. Reports Q4 and FY 2023 Financial Results — 6-K · Mar 7, 2024 Risk: low
  Evogene Ltd. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023, on March 7, 2024. The company, incorporated in Isra
• Evogene Subsidiary Ag Plenus Appoints Dr. Dan Jacob Gelvan as CEO — 6-K · Feb 22, 2024 Risk: low
  Evogene Ltd. announced on February 22, 2024, changes in the management of its subsidiary, Ag Plenus Ltd. Dr. Dan Jacob Gelvan will be appointed as the new Chief
• Evogene Subsidiary Ag Plenus Partners with Bayer for Weed Control — 6-K · Feb 21, 2024 Risk: low
  Evogene Ltd. announced on February 21, 2024, that its subsidiary, Ag Plenus Ltd., has entered into a Licensing and Collaboration Agreement with Bayer AG. This a
• SC 13G Filing — SC 13G · Feb 14, 2024
• Evogene's Biomica Completes Phase I Enrollment for Cancer Drug BMC128 — 6-K · Jan 17, 2024
  Evogene Ltd.'s subsidiary, Biomica Ltd., announced on January 17, 2024, that it successfully completed Phase I trial enrollment for its microbiome-based immuno-
• Evogene Files Investor Presentation, CEO Haviv to Present — 6-K · Jan 9, 2024
  Evogene Ltd. filed a 6-K on January 9, 2024, to include an investor presentation dated January 10, 2024. This presentation, led by President & CEO Ofer Haviv, l

Related Companies

ICL

Frequently Asked Questions